Avalo Therapeutics (AVTX) Free Cash Flow (2014 - 2026)
Avalo Therapeutics (AVTX) posted Free Cash Flow of -$17.7 million for Q1 2026, down 23.88% on a QoQ basis from -$14.3 million in Q4 2025, and down 87.16% year-over-year from -$137.9 million in Q1 2025.
Avalo Therapeutics (AVTX) Free Cash Flow (2014 - 2026) Analysis & Trends
Avalo Therapeutics' Free Cash Flow history runs 13 years deep, the most recent figure standing at -$17.7 million for Q1 2026.
- Quarterly Free Cash Flow fell 87.16% year-over-year to -$17.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$59.7 million (down 14.21% YoY) and the FY2025 annual result came in at -$51.5 million, down 4.98% from the prior year.
- Free Cash Flow was -$17.7 million for Q1 2026 at Avalo Therapeutics, down from -$14.3 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $5.8 million in Q3 2022 and bottomed at -$17.7 million in Q1 2026.
- A 5-year average of -$10.3 million and a median of -$11.3 million in 2025 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow surged 131.65% — and 2024, when it slumped 443.89%.
- Avalo Therapeutics' Free Cash Flow stood at -$4.0 million in 2022, then surged by 31.45% to -$2.8 million in 2023, then slumped by 443.89% to -$15.0 million in 2024, then increased by 5.03% to -$14.3 million in 2025, then decreased by 23.88% to -$17.7 million in 2026.
- Business Quant data shows AVTX's Free Cash Flow at -$17.7 million in Q1 2026, -$14.3 million in Q4 2025, and -$16.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Avalo Therapeutics | 1.04 Mn | 1.04 Mn | - | -17.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.70 Mn |
| Mar 31, 2026 | -17.70 Mn |
| Dec 31, 2025 | -14.29 Mn |
| Dec 31, 2025 | -14.29 Mn |
| Sep 30, 2025 | -16.41 Mn |
| Sep 30, 2025 | -16.41 Mn |
| Jun 30, 2025 | -11.34 Mn |
| Jun 30, 2025 | -11.34 Mn |
| Mar 31, 2025 | -9.46 Mn |
| Mar 31, 2025 | -9.46 Mn |
| Dec 31, 2024 | -15.04 Mn |
| Dec 31, 2024 | -15.04 Mn |
| Sep 30, 2024 | -11.53 Mn |
| Sep 30, 2024 | -11.53 Mn |
| Jun 30, 2024 | -16.28 Mn |
| Jun 30, 2024 | -16.28 Mn |
| Mar 31, 2024 | -6.20 Mn |
| Mar 31, 2024 | -6.20 Mn |
| Dec 31, 2023 | -2.77 Mn |
| Dec 31, 2023 | -2.77 Mn |